NASDAQ$TSHA
Taysha Gene Therapies Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Taysha Gene Therapies reported Q1 2025, revenue of $2.3M, net loss of $21.5M, diluted EPS of $-0.08.
For Q1 2025, Taysha Gene Therapies reported revenue of $2.3M, a net loss of $21.5M, diluted EPS was $-0.08. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Q1 2025 revenue $2.3M.
- Net loss $21.5M.
- Diluted EPS $-0.08.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$2.3M
Forward guidance
Clinical-stage biotech filers emphasize trial milestones, regulatory paths, and cash runway; product revenue is limited or absent.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into upcoming catalysts.
- Regulatory designations where applicable.
Headwinds
- Trial failure or regulatory delay risk.
- Dilution from equity raises.
- No near-term product revenue for most programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro